Complement system: a neglected pathway in immunotherapy
A Bordron, C Bagacean, A Tempescul… - Clinical reviews in …, 2020 - Springer
Approved for the treatment of autoimmune diseases, hematological malignancies, and solid
cancers, several monoclonal antibodies (mAb) make use of complement in their mechanism …
cancers, several monoclonal antibodies (mAb) make use of complement in their mechanism …
A multicentric Castleman disease associated with mixed warm and cold antibody-mediated aha responsive to siltuximab
F Plano, S Mancuso, GM Camarda, MG Butera… - Chemotherapy, 2024 - karger.com
Castleman disease is non-clonal lymphoproliferative disorders defined by hypertrophy of
lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are …
lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are …
[PDF][PDF] Case Report A Multicentric Castleman disease associated with mixed warm and cold antibody–mediated AHA responsive to siltuximab
F Plano, S Mancuso, GM Camarda, MG Butera… - researchgate.net
Castleman disease (CD) is nonclonal lymphoproliferative disorders defined by hypertrophy
of lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are …
of lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are …